July 14, 2025

Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Treatment with TP-0903 and decitabine shows varied responses in elderly patients with acute myeloid leukemia.
KEY EVIDENCE: Responders demonstrate significantly different pharmacokinetic profiles compared to non-responders.
APPROACH: Study investigated plasma levels and their correlation with toxicity in patients aged 60 and above.
SIGNIFICANCE: Understanding treatment efficacy and side effects is crucial for improving outcomes in older adults with leukemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Clinical trial assesses pharmacokinetics and toxicity in patients with acute myeloid leukemia, suggesting dosing impacts response rates.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark